B cell depletion is typically achieved through the use of monoclonal antibodies that target specific proteins on the surface of B cells. One of the most common targets is the CD20 protein, found on the surface of mature B cells. Medications like Rituximab and Ocrelizumab bind to CD20, leading to the destruction of these B cells.
